Partnered Products and Programs

Our partners are advancing several compounds in clinical trials that were the outcome of previous drug discovery collaborations with Astex including three drugs that have now been approved. The responsibility for developing these products is with our partners.

Discovery	Phase 1	Phase 2	Phase 3	Marketed

CDK4/6 inhibitor (Oncology)
Partner: Novartis

.	.	.	.	.

FGFr inhibitor (Oncology)
Partner: Janssen

.	.	.	.	.

PKB/Akt Inhibitor (Oncology)
Partner: AstraZeneca

.	.	.	.	.

Partner: MSD and Taiho

G12C:

.	.	.	.

Other mutants:

.

Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
Partner: Mosaic Therapeutics

.	.	.

Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
Partner: Mosaic Therapeutics

.	.

Partner: MSD and Taiho

.	.

Partner: MSD

.